Comparison of Two Antiplatelet Therapy Strategies in Patients Undergoing Transcatheter Aortic Valve Implantation

The objective of this study was to compare 2 strategies of antiplatelet therapy in patients undergoing TAVI. A strategy using monoantiplatelet therapy (group A, n = 164) was prospectively compared with a strategy using dual antiplatelet therapy (group B, n = 128) in 292 consecutive patients undergoing TAVI. The primary end point was a combination of mortality, major stroke, life-threatening bleeding (LTB), myocardial infarction, and major vascular complications at 30 days. All adverse events were adjudicated according to the Valve Academic Research Consortium. The primary end point occurred in 22 patients (13.4%) in the group A and in 30 patients (23.4%) in the group B (hazard ratio 0.51, 95% confidence interval 0.28 to 0.94, p = 0.026). LTB (3.7% vs 12.5%, p = 0.005) and major bleedings (2.4% vs 13.3%, p

Source: The American Journal of Cardiology - October 28, 2013 Category: Cardiology Authors: Eric Durand, Didier Blanchard, Stephan Chassaing, Martine Gilard, Marc Laskar, Bogdan Borz, Antoine Lafont, Christophe Barbey, Matthieu Godin, Christophe Tron, Rachid Zegdi, Didier Chatel, Olivier Le Page, Pierre-Yves Litzler, Jean-Paul Bessou, Nicolas Da Tags: Valvular Heart Disease Source Type: research